During the corresponding time, Infusystem Holdings Inc recorded a revenue increase by 2.59 % year on year, sequentially revenue grew by 9.65 %. While revenue at the Infusystem Holdings Inc's corporate clients
Infusystem Holdings Inc's Comment on Sales, Marketing and Customers
InfuSystem provides healthcare providers with durable medical equipment (DME) and treatment consumables, manages order and delivery logistics, offers 24/7 nursing support, handles third-party payer DME billing, and delivers biomedical services including inspection, repair, certification, and replacement. Their Device Solutions are offered as a concierge service on a direct payer model, encompassing equipment rental and sales, consumable sales, and biomedical support. InfuSystem serves physicians, outpatient oncology practices, hospitals, outpatient surgery centers, homecare practices, patient rehabilitation centers, and patients in the U.S. and Canada. As of December 31, 2025, the company has established relationships with nearly 840 third-party payer networks and operates seven geographic locations across the U.S. and Canada to facilitate prompt delivery.
The Patient Services segment focuses on clinic-to-home healthcare solutions by leveraging DME, logistics, billing, and clinical and biomedical capabilities. Its primary service involves supplying electronic ambulatory infusion pumps and disposable supply kits to private oncology clinics, infusion clinics, and hospital outpatient oncology clinics for treating various cancers, including colorectal cancer. The segment aims to expand services to additional cancer types. Customers and markets referenced include the American Cancer Society.
Infusystem Holdings Inc’s Comment on Sales, Marketing and Customers
InfuSystem provides healthcare providers with durable medical equipment (DME) and treatment consumables, manages order and delivery logistics, offers 24/7 nursing support, handles third-party payer DME billing, and delivers biomedical services including inspection, repair, certification, and replacement. Their Device Solutions are offered as a concierge service on a direct payer model, encompassing equipment rental and sales, consumable sales, and biomedical support. InfuSystem serves physicians, outpatient oncology practices, hospitals, outpatient surgery centers, homecare practices, patient rehabilitation centers, and patients in the U.S. and Canada. As of December 31, 2025, the company has established relationships with nearly 840 third-party payer networks and operates seven geographic locations across the U.S. and Canada to facilitate prompt delivery.
The Patient Services segment focuses on clinic-to-home healthcare solutions by leveraging DME, logistics, billing, and clinical and biomedical capabilities. Its primary service involves supplying electronic ambulatory infusion pumps and disposable supply kits to private oncology clinics, infusion clinics, and hospital outpatient oncology clinics for treating various cancers, including colorectal cancer. The segment aims to expand services to additional cancer types. Customers and markets referenced include the American Cancer Society.
Sources:
Infusystem Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Infusystem Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Infusystem Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
126.97 %